| Chen, Yen-Lin |
NCT05861440: Applying Shear Wave Elastography for Adjunct Steroid on Tuberculous Lymphadenitis |
|
|
| Recruiting | N/A | 50 | RoW | Prednisolone, standard anti-tuberculosis agents | National Taiwan University Hospital | Tuberculous Lymphadenitis | 07/25 | 12/25 | | |
NCT04560803: Epidermal Skin Grafts to Improve Healing In Radiation Wounds |
|
|
| Recruiting | N/A | 34 | US | CelluTomeTM Epidermal Harvesting System | Massachusetts General Hospital, 3M | Radiation Dermatitis | 03/28 | 12/28 | | |
| Schiffer, Fredric - |
NCT05995873: A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders. |
|
|
| Recruiting | N/A | 130 | US | unilateral transcranial photobiomodulation | MindLight, LLC, Mclean Hospital | Opioid Use Disorder, Moderate, Opioid Use, Opioid Dependence, Opioid Abuse, Opiate Dependence, Opioid Use, Unspecified | 08/24 | 08/24 | | |
| Johnston, Andrea |
| Recruiting | 3 | 300 | US | Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Esophagectomy, excision of the esophagus, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, FOLFOX regimen, FOLFOX, CAPOX regimen, CAPE-OX, OxCap, Docetaxel, Taxotere, 5FU, 5-FU, flurouracil, Tolak, Fluoroplex, Efudex, Carac, Adrucil | NRG Oncology, National Cancer Institute (NCI) | Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma | 12/26 | 12/31 | | |
HERO, NCT05705401: Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer |
|
|
| Recruiting | 3 | 1300 | US | Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation | NRG Oncology, National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, SWOG Cancer Research Network | HER2-positive Breast Cancer | 02/34 | 02/37 | | |
| Teicher, Martin H |
| Completed | N/A | 500 | US | Maltreatment and Abuse Chronology of Exposure Scale as a stress challenge, Standardized Maths and Verbal Questions such as the ones used in SATs, Chronology of Perceived Discrimination Scale (CPDS), International Personality Item Pool (IPIP-NEO) | Mclean Hospital | Stress, Psychological, Stress, Emotional | 12/23 | 12/23 | | |
NCT05209217: Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder |
|
|
| Recruiting | N/A | 20 | US | Ketamine | Mclean Hospital, Juvenile Bipolar Research Foundation | Bipolar Disorder | 12/22 | 01/23 | | |
| Wang, Ying |
NCT05071482: Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL |
|
|
| Recruiting | 4 | 238 | RoW | Flumatinib, Imatinib | wang, jianxiang | Acute Leukemia | 10/25 | 10/25 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
MELATORCH, NCT03430297: A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma |
|
|
| Completed | 3 | 256 | RoW | JS001 240mg Q2W, Dacarbazine 1000mg/m2 Q3W | Shanghai Junshi Bioscience Co., Ltd. | Metastatic Melanoma, Unresectable Melanoma | 07/23 | 11/23 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
NCT05904964: Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial) |
|
|
| Recruiting | 3 | 288 | RoW | Disitamab vedotin, RC48, Endocrine therapy | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | HR Positive/HER2 Low Expression Metastatic Breast Cancer | 03/28 | 03/30 | | |
NCT04646759: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 516 | RoW | Fulvestrant combined with Pyrotinib, FASLODEX combined with Pyrotinib, Capecitabine combined with Pyrotinib, xeloda combined with Pyrotinib | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 12/28 | 12/30 | | |
NCT06083623: A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants |
|
|
| Not yet recruiting | 2b | 2250 | RoW | TNM001, placebo | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory Syncytial Virus Infections | 05/26 | 08/26 | | |
2019-KY-049, NCT04034589: Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer |
|
|
| Recruiting | 2 | 46 | RoW | Pyrotinib combined with fulvestrant | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Metastatic Breast Cancer | 07/21 | 07/22 | | |
NCT06429098: Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML |
|
|
| Recruiting | 2 | 40 | RoW | Venetoclax, ABT-199, ABT199, Venclexta, azacitidine, 5 AZC, 5-AZC, decitabine, Dacogen, Cytarabine, 1-.beta.-Cytosine arabinoside, Ara-C | The First Affiliated Hospital of Soochow University | Acute Myeloid Leukemia | 06/27 | 12/27 | | |
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC |
|
|
| Recruiting | 2 | 50 | RoW | Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT) | Chongqing University Cancer Hospital | Non-Small Cell Lung Cancer (NSCLC) | 03/24 | 08/24 | | |
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC |
|
|
| Recruiting | 2 | 60 | RoW | HLX07+HLX10+ Cisplatin+5-FU, HLX07 | Shanghai Henlius Biotech | ESCC or Esophageal Adenosquamous Carcinoma | 06/24 | 08/25 | | |
| Recruiting | 2 | 39 | RoW | Camrelizumab, Anti-PD-1 antibody, Stereotactic body radiotherapy, SBRT | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma | 08/24 | 08/26 | | |
| Recruiting | 2 | 22 | RoW | Anti-CD7 CAR-T | Ying Wang | Hematological Malignancies | 09/24 | 09/25 | | |
| Recruiting | 2 | 60 | RoW | Olverembatinib, Venetoclax, prednisone, Vincristine | Institute of Hematology & Blood Diseases Hospital, China | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | 10/24 | 03/25 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05660473: Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 2 | 100 | RoW | Vincristine, Daunorubicin, Cyclophosphamide, Pegaspargase, Prednisone, Cytarabine, 6-mercaptopurine, Dexamethasone, Methotrexate, Venetoclax | Institute of Hematology & Blood Diseases Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12/24 | 12/27 | | |
NCT05213884: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC |
|
|
| Recruiting | 2 | 30 | RoW | Camrelizumab, Anti-PD-1 antibody, Concurrent cisplatin chemotherapy, Intensity-modulated radiotherapy (IMRT) | Chongqing University Cancer Hospital | Head and Neck Squamous Cell Carcinoma | 01/25 | 01/27 | | |
NCT06059261: Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. |
|
|
| Recruiting | 2 | 45 | RoW | Envafolimab and recombinant human endostatin combined with chemoradiotherapy | Chongqing University Cancer Hospital, Fujian Cancer Hospital, Sun Yat-sen University | Nasopharyngeal Carcinoma | 10/27 | 10/27 | | |
NCT06776757: Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer |
|
|
| Recruiting | 1/2 | 30 | RoW | Sintilimab+Cetuximab+Chemotherapy (mFOLFOX6/FOLFIRI/CAPEOX/CAPIRI) | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Metastatic Colorectal Cancer | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 203 | RoW | CN201, CN201 for Injection | Curon Biopharmaceutical (Shanghai) Co.,Ltd | Acute Lymphoblastic Leukemia | 05/25 | 07/25 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT06608329: A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 33 | RoW | HDM1002 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Healthy Adult Subject | 11/24 | 12/24 | | |
NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 153 | RoW | HRS-1167 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/24 | | |
NCT05360043: Efficacy and Safety of 1565-nm Non-ablative Fractional Laser Versus Long-pulsed 1064-nm Nd:YAG Laser in the Treatment of Enlarged Facial Pores |
|
|
| Recruiting | N/A | 27 | RoW | laser treatment | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enlarged Facial Pores | 04/22 | 10/22 | | |
NCT04800575: Comparison of Sterile Gauze and Semi-permeable Film Dressing for Hemodialysis Central Venous Catheter |
|
|
| Recruiting | N/A | 154 | RoW | semi-permeable film, sterile gauze and tape | Peking University People's Hospital | Infection, Bacterial | 05/22 | 12/22 | | |
NCT04008524: A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies |
|
|
| Available | N/A | | RoW | CAR-T cells | Institute of Hematology & Blood Diseases Hospital, Juventas Cell Therapy Ltd. | Relapsed and Refractory Hematological Malignancies | | | | |
HRQoL, NCT03926858: Patient-reported Outcomes of Postsurgical Pain and Health Related Quality of Life |
|
|
| Completed | N/A | 2000 | RoW | | Peking University People's Hospital | Post Surgical Pain | 05/23 | 05/23 | | |
| Recruiting | N/A | 100 | RoW | Prebiotic fructans, Non-prebiotic maltodextrin | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Beneo GmbH | Constipation | 12/22 | 12/22 | | |
NCT04880083: Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein |
|
|
| Completed | N/A | 120 | RoW | Commercially Available Starter Infant Formula | Société des Produits Nestlé (SPN), Medrio, Inc, SAS Institute, Veeva Systems | Digestion, Gut Microbiota | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | RoW | Automated peritoneal dialysis, Intermittent hemodialysis | Limeng Chen, First Hospital of China Medical University, First Affiliated Hospital Xi'an Jiaotong University, Beijing Anzhen Hospital, Xiangya Hospital of Central South University, Baxter Healthcare Corporation | Acute Kidney Injury | 12/22 | 12/22 | | |
| Recruiting | N/A | 206 | RoW | automated peritoneal dialysis, IHD | Peking Union Medical College Hospital, First Hospital of China Medical University, Beijing Anzhen Hospital, The Luhe Teaching Hospital of the Capital Medical University, Ningbo No.2 Hospital | ESRD | 12/22 | 02/23 | | |
NCT05540795: Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT |
|
|
| Completed | N/A | 15 | RoW | | Fifth Affiliated Hospital, Sun Yat-Sen University | Parathyroid Gland Disease, Secondary Hyperparathyroidism | 05/23 | 07/23 | | |
NCT06167109: NBI Combined With MRI to Guide CTV Optimization in Eccentric Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 60 | RoW | CTV optimized IMRT | Chongqing University Cancer Hospital | Nasopharyngeal Carcinoma by AJCC V8 Stage | 05/26 | 10/26 | | |
NCT05014893: Neural Mechanisms of Cognitive Assessment and Rehabilitation for Cognitive Decline |
|
|
| Recruiting | N/A | 100 | RoW | multi-modal targeted intervention (e.g., cognitive training, exercise, games) | National Research Center for Rehabilitation Technical Aids, Nanjing Brain Hospital, The Third People's Hospital of Yunnan Province, Central South University, Beijing academy of science and technology, Beijing University of Chinese Medicine | Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD), Aging, Healthy | 12/26 | 12/26 | | |
NCT06511453: Acupressure in Patients With Sickle Cell Disease |
|
|
| Recruiting | N/A | 240 | US | Acupressure (using AcuWand or pencil eraser) | Indiana University, University of California, Irvine | Sickle Cell Disease | 02/29 | 08/29 | | |
NCT05992285: A Clinical Study of Theta Burst Stimulation (cTBS) in the Treatment of Insomnia Disorder Targeting the Dentate Nucleus of the Cerebellum |
|
|
| Completed | N/A | 68 | RoW | transcranial magnetic stimulation | Xijing Hospital, First Affiliated Hospital of Xi'an Medical University, Xi'an No.1 Hospital, Xi'an International Medical Center Hospital, Xi'an Hospital of Traditional Chinese Medicine | Insomnia Disorder | 10/24 | 10/24 | | |
NCT05961566: Palatal Volumetric Change Analysis Following Connective Tissue Graft With and Without Donor Site Augmentation |
|
|
| Recruiting | N/A | 40 | US | Use of collagen matrix after subepithelial connective tissue graft harvest, Helistat - collagen matrix group, Experimental | Hailey Bivens | Recession, Gingival | 09/24 | 03/25 | | |
| Recruiting | N/A | 500 | RoW | 18F-S16/T807 | Tianjin Medical University, Tianjin Medical University General Hospital | Tauopathies, Neurodegenerative Diseases, Neurodegeneration | 11/27 | 12/27 | | |
NCT06725719: Translocator Protein PET/CT in Various TSPO-Related Disease |
|
|
| Recruiting | N/A | 200 | RoW | 18F-DPA714/FDPA | Tianjin Medical University, Tianjin Medical University General Hospital | Neuroinflammation, Stroke, Neurodegenerative Diseases | 12/27 | 12/27 | | |
NCT06725706: Beta Amyloid PET/CT in Various Aβ-Related Disease |
|
|
| Recruiting | N/A | 500 | RoW | 18F-92/AV45, 11C-PIB | Tianjin Medical University, Tianjin Medical University General Hospital | Amyloid, Beta-Amyloid, Neurodegenerative Diseases | 12/27 | 12/27 | | |
NCT05483790: The Effects of Multidomain Non-pharmacological Interventions on the Elderly With or Without Mild Cognitive Impairment |
|
|
| Active, not recruiting | N/A | 112 | RoW | the multimodal intervention | Huashan Hospital, School of Public Health，Fudan University, Medicine-Mental Health Center of Minhang District, Xinzhuang Community Health Service Center | Mild Cognitive Impairment, The Cognitive Normal Elderly | 12/24 | 12/24 | | |
NCT06725550: Integrative Medicine in Pain Management in Sickle Cell Disease |
|
|
| Not yet recruiting | N/A | 120 | US | needling acupuncture, laser acupuncture | Indiana University | Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy | 02/29 | 02/30 | | |
NCT05045820: Integrative Medicine in Pain Management in Sickle Cell Disease |
|
|
| Recruiting | N/A | 60 | US | needling acupuncture, laser acupuncture | Indiana University, National Center for Complementary and Integrative Health (NCCIH) | Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy | 05/25 | 05/26 | | |
NCT04683757: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer |
|
|
| Recruiting | N/A | 288 | RoW | Establishment of a Survival Prediction Model | Ying Wang | Breast Cancer | 01/21 | 12/24 | | |
NCT04683445: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer |
|
|
| Recruiting | N/A | 80 | RoW | Eribulin, Halaven, Trastuzumab, Herceptin, pertuzumab, Perjeta, Pyrotinib, Pembrolizumab, Keytruda, Camerlizumab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 12/22 | 12/23 | | |
| Recruiting | N/A | 1000 | RoW | Carotid revascularization, carotid endarterectomy and carotid artery stent, MRI-PWI, CTA, PET/MRI, Ultrasound | Peking Union Medical College Hospital | Carotid Artery Stenosis | 12/25 | 12/26 | | |
| Anderson, R Rox |
NCT04730583: Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Active, not recruiting | 1 | 20 | US | Kybella, 1064nm laser, 755nm Alexandrite Laser | Massachusetts General Hospital, Johns Hopkins University | Cutaneous Neurofibroma | 12/24 | 12/24 | | |
| Recruiting | N/A | 343 | US | CardiAMP Cell Therapy System, Sham Treatment | BioCardia, Inc. | Refractory Angina, Chronic Myocardial Ischemia | 07/25 | 12/26 | | |
NCT01873131: A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn |
|
|
| Recruiting | N/A | 126 | US | topical timolol maleate, timolol, beta blocker, Pulsed dye laser, PDL | Massachusetts General Hospital | Hemangioma | 12/25 | 12/28 | | |
| Recruiting | N/A | 650 | Europe, Canada, Japan, US, RoW | Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) | Medtronic Cardiovascular | Moderate Aortic Valve Stenosis | 02/26 | 12/34 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
| Sakamoto, Fernanda H |
NCT06132165: Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Recruiting | 1 | 30 | US | Deoxycholic Acid, Kybella, Polidocanol, Asclera, 1064nm Nd:YAG laser, 755nm Alexandrite Laser | Massachusetts General Hospital, Johns Hopkins University | Neurofibromatosis 1 | 10/24 | 10/24 | | |
NCT06120036: Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Recruiting | 1 | 20 | US | Kybella, Asclera | Massachusetts General Hospital, Johns Hopkins University | Neurofibromatosis 1 | 04/24 | 09/24 | | |
| Anderson, Richard R |
NCT06132165: Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Recruiting | 1 | 30 | US | Deoxycholic Acid, Kybella, Polidocanol, Asclera, 1064nm Nd:YAG laser, 755nm Alexandrite Laser | Massachusetts General Hospital, Johns Hopkins University | Neurofibromatosis 1 | 10/24 | 10/24 | | |
NCT06120036: Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Recruiting | 1 | 20 | US | Kybella, Asclera | Massachusetts General Hospital, Johns Hopkins University | Neurofibromatosis 1 | 04/24 | 09/24 | | |
NCT06300502: Assessing the Efficacy of Repeat, Monthly Treatments of Cutaneous Neurofibromas (cNFs) |
|
|
| Not yet recruiting | 1 | 10 | US | Kybella, Deoxycholate, Asclera, Polidocanol, 755nm Alexandrite Laser, 1064nm Nd:YAG Laser | Massachusetts General Hospital, Johns Hopkins University | Neurofibromas, Cutaneous, Neurofibromatosis 1 | 12/25 | 12/25 | | |
NCT01910818: Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury |
|
|
| Active, not recruiting | N/A | 12 | US | Fractional CO2 laser treatment, Lumenis Ultrapulse CO2 laser, No treatment | Massachusetts General Hospital | Chronic Radiation Dermatitis | 08/25 | 08/26 | | |
| Tran, Thanh-Nga T |
| Active, not recruiting | N/A | 75 | US | MIRIA Laser | AVAVA, Inc. | Acne Scars - Mixed Atrophic and Hypertrophic | 02/25 | 02/25 | | |
| Dammin, Beverly |
NCT04730583: Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas |
|
|
| Active, not recruiting | 1 | 20 | US | Kybella, 1064nm laser, 755nm Alexandrite Laser | Massachusetts General Hospital, Johns Hopkins University | Cutaneous Neurofibroma | 12/24 | 12/24 | | |
NCT05841628: Tolerability of 532 nm Laser Treatment of Port Wine Stains |
|
|
| Recruiting | N/A | 15 | US | 532 nm laser treatment | Massachusetts General Hospital | Port-Wine Stain | 08/24 | 12/24 | | |
